Brokerages Set Bicara Therapeutics Inc. (NASDAQ:BCAX) PT at $43.00

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have been given an average rating of “Buy” by the seven ratings firms that are currently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $43.00.

A number of research firms recently weighed in on BCAX. Morgan Stanley started coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price objective for the company. HC Wainwright began coverage on shares of Bicara Therapeutics in a research note on Friday, December 6th. They issued a “buy” rating and a $42.00 price target on the stock. Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set a “buy” rating and a $47.00 price objective for the company. TD Cowen began coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating on the stock. Finally, Rodman & Renshaw assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating and a $48.00 price target for the company.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in BCAX. Cinctive Capital Management LP purchased a new stake in Bicara Therapeutics during the 3rd quarter valued at $229,000. Barclays PLC purchased a new stake in Bicara Therapeutics during the third quarter valued at $255,000. Jane Street Group LLC bought a new position in Bicara Therapeutics in the third quarter valued at about $309,000. Teachers Retirement System of The State of Kentucky purchased a new position in Bicara Therapeutics in the third quarter worth about $358,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Bicara Therapeutics in the third quarter worth about $462,000.

Bicara Therapeutics Trading Down 7.0 %

BCAX stock opened at $17.00 on Thursday. Bicara Therapeutics has a one year low of $16.01 and a one year high of $28.09. The business’s 50 day simple moving average is $20.54.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, analysts anticipate that Bicara Therapeutics will post -2.59 EPS for the current year.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.